| Daratumumab, lenalidomide, and dexamethasone for multiple myeloma MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ... New England Journal of Medicine 375 (14), 1319-1331, 2016 | 1581 | 2016 |
| Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ... New England Journal of Medicine 374 (17), 1621-1634, 2016 | 1217 | 2016 |
| Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari, NJ Bahlis, A Belch, ... The Lancet 387 (10027), 1551-1560, 2016 | 973 | 2016 |
| Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma L Benboubker, MA Dimopoulos, A Dispenzieri, J Catalano, AR Belch, ... New England Journal of Medicine 371 (10), 906-917, 2014 | 908 | 2014 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 871 | 2019 |
| A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma DS Siegel, T Martin, M Wang, R Vij, AJ Jakubowiak, S Lonial, S Trudel, ... Blood, The Journal of the American Society of Hematology 120 (14), 2817-2825, 2012 | 808 | 2012 |
| Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma SZ Usmani, BM Weiss, T Plesner, NJ Bahlis, A Belch, S Lonial, ... Blood, The Journal of the American Society of Hematology 128 (1), 37-44, 2016 | 498 | 2016 |
| Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study PG Richardson, DS Siegel, R Vij, CC Hofmeister, R Baz, S Jagannath, ... Blood, The Journal of the American Society of Hematology 123 (12), 1826-1832, 2014 | 447 | 2014 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 435 | 2016 |
| Teclistamab in relapsed or refractory multiple myeloma P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ... New England Journal of Medicine 387 (6), 495-505, 2022 | 430 | 2022 |
| Ascorbic acid enhances arsenic trioxide–induced cytotoxicity in multiple myeloma cells JM Grad, NJ Bahlis, I Reis, MM Oshiro, WS Dalton, LH Boise Blood, The Journal of the American Society of Hematology 98 (3), 805-813, 2001 | 370 | 2001 |
| An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma R Vij, M Wang, JL Kaufman, S Lonial, AJ Jakubowiak, AK Stewart, ... Blood, The Journal of the American Society of Hematology 119 (24), 5661-5670, 2012 | 312 | 2012 |
| Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma T Facon, MA Dimopoulos, A Dispenzieri, JV Catalano, A Belch, M Cavo, ... Blood, The Journal of the American Society of Hematology 131 (3), 301-310, 2018 | 280 | 2018 |
| Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label … S Grosicki, M Simonova, I Spicka, L Pour, I Kriachok, M Gavriatopoulou, ... The Lancet 396 (10262), 1563-1573, 2020 | 255 | 2020 |
| Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study NJ Bahlis, MA Dimopoulos, DJ White, L Benboubker, G Cook, M Leiba, ... Leukemia 34 (7), 1875-1884, 2020 | 246 | 2020 |
| A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma NC Munshi, H Avet-Loiseau, KC Anderson, P Neri, B Paiva, M Samur, ... Blood advances 4 (23), 5988-5999, 2020 | 241 | 2020 |
| Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma NJ Bahlis, J McCafferty-Grad, I Jordan-McMurry, J Neil, I Reis, ... Clinical cancer research 8 (12), 3658-3668, 2002 | 241 | 2002 |
| Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX MA Dimopoulos, J San-Miguel, A Belch, D White, L Benboubker, G Cook, ... haematologica 103 (12), 2088, 2018 | 236 | 2018 |
| Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13 D Reece, KW Song, T Fu, B Roland, H Chang, DE Horsman, A Mansoor, ... Blood, The Journal of the American Society of Hematology 114 (3), 522-525, 2009 | 232 | 2009 |
| An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib R Vij, DS Siegel, S Jagannath, AJ Jakubowiak, AK Stewart, K McDonagh, ... British journal of haematology 158 (6), 739-748, 2012 | 224 | 2012 |
